Celther Polskasp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2008-08-20
Share capital
100,000.00 PLN
Activity description

Celther Polska offers DibuCell Active Exudate dressings to support the treatment of wounds without visible signs of infection. They are intended for flat, shallow ulcers and skin injuries, among other uses.

Registered address
ul. Inwestycyjna 7, 95-050 Konstantynów Łódzki, Poland
Phone
Electronic delivery address
AE:PL-51658-29681-BDCIJ-27

Financials

Revenue history (in k)

Filing timeliness

3 of 6 financial statements were filed late (the longest delay 270 days for 2023).

  • 202502/07/2026
  • 202408/07/2025
  • 202311/04/2025
  • 202204/08/2023
  • 202113/09/2022
  • 202015/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 2.77mMedianUSD 55.24kAverageUSD 2.71m
Net profit
This companyUSD 60.15kMedianUSD -1.27kAverageUSD -91.85k
Operating costs
This companyUSD 2.55mMedianUSD 65.85kAverageUSD 2.66m
Assets
This companyUSD 22.37mMedianUSD 133.19kAverageUSD 3.03m

Trademarks

Celther Polska holds 1 active trademark registered with the Polish Patent Office. 3 marks have expired or were not registered. The first mark was filed in 2013.

MarkNumberClassesStatusProtected until
be.MelZ.5995793Protected Mar 17, 2036
SUDOCELLZ.5423513, 5Proceedings discontinued –
CUDOCELL MAX Pielęgnuję, bo kocham.Z.5278133, 5Not registered –
Celther POLSKAZ.4232241, 3, 5, 10, 39, 41, 42, 44, 45Proceedings discontinued –
MarkProtected until
be.MelMar 17, 2036
SUDOCELL–
CUDOCELL MAX Pielęgnuję, bo kocham.–
Celther POLSKA–

Authorized Representatives

Andrzej Szczepan Wyrzykowski – President of the Management Board
Dominika Wyrzykowska – Attorney-in-fact (sole)

Manner of representation

To make declarations and sign on behalf of the company, the following is authorized: 1. in the case of a one-person management board, the President of the Management Board acting independently; 2. in the case of a multi-member management board: two members of the management board acting jointly or a member of the management board acting jointly with a commercial proxy.

Ownership

OwnerSharesShare valueStake
Piotr Rieskeage 55
30$4,051.8615%
160$21,609.9480%
Others
10$1,350.625%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2008-09-26.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Land (incl. perpetual usufruct)
$170.3K
Buildings and premises
$2.8M

Public aid

33 public aid cases recorded, with a total value of $41,448.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$30
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$6,861
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$6,756

Regulatory authorisations

AuthorityTypeStatus
Waste generation Active

Competitors

Name
BiotechnaS.A.
SkinlabP.S.A.
Enamine Plsp. z o.o.
Read-GeneS.A.
Medict Institute Opinie Lekarskie Orzeczeniasp. z o.o.
Proteon PharmaceuticalsS.A.
Gravidasp. z o.o.
Iclabsp. z o.o.
EIT Rawmaterials Clc Eastsp. z o.o.
Warsaw Genomicssp. z o.o.

Change history

DateEvent
2017-04-26Share capital increase
2016-10-28Address change
2015-08-18PKD change
2013-01-23Share capital increase
2008-08-20Entered in the register

FAQ

Last updated: 2026-07-04